Pfizer R&D In China: Building A Virtual R&D Network

While many multinational companies have taken a brick-and-mortar approach to R&D in emerging markets, Pfizer is betting that a virtual research network will give it the flexibility and access to talent it needs to succeed in China. Pfizer's president of global R&D, Martin Mackay, and Stephen Yang, who heads Pfizer's Asia R&D efforts, outline that strategy in a two-part interview. Two of the most important figures in Pfizer's worldwide research endeavors, Mackay and Yang were interviewed by Elsevier writers Ellen Licking and Wendy Diller. This is part one of the interview; part two will appear in an upcoming issue of PharmAsia News.